Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Adamis Pharmaceuticals Corporation | ADMP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 0.119 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.119 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.0992 - 0.62 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.119 | USD |
Adamis Pharmaceuticals Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 19.81M | 166.48M | 165.91M | $ 4.85M | $ - | -0.19 | -1.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | 5.70% |
Adamis Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADMP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.1047 | 0.13 | 0.0992 | 0.1123284 | 1,041,929 | 0.0143 | 13.66% |
| 1 Month | 0.29 | 0.31 | 0.0992 | 0.17631 | 2,778,502 | -0.171 | -58.97% |
| 3 Months | 0.1648 | 0.31 | 0.0992 | 0.1889181 | 1,378,804 | -0.0458 | -27.79% |
| 6 Months | 0.2619 | 0.31 | 0.0992 | 0.1734556 | 1,540,343 | -0.1429 | -54.56% |
| 1 Year | 0.62 | 0.62 | 0.0992 | 0.2480944 | 1,122,254 | -0.501 | -80.81% |
| 3 Years | 0.40 | 2.34 | 0.0992 | 1.01 | 4,629,473 | -0.281 | -70.25% |
| 5 Years | 3.45 | 5.10 | 0.0992 | 1.10 | 3,083,946 | -3.33 | -96.55% |
Adamis Pharmaceuticals Description
| Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19. |